Gepotidacin outperformed nitrofurantoin most clearly when the uropathogen was nitrofurantoin non-susceptible

The edition in brief

A Clinical Infectious Diseases analysis, published on 28 October, pooled the EAGLE-2 and EAGLE-3 trials of gepotidacin 1,500 mg twice daily against nitrofurantoin 100 mg twice daily for five days in women and girls aged 12 or over with uncomplicated UTI. Therapeutic success favoured gepotidacin by 9.6 points with nitrofurantoin-susceptible organisms and by 20.8 points with non-susceptible ones, driven by microbiological rather than symptomatic response; subgroups at higher resistance risk showed similar or better results. It is industry-sponsored subgroup work, and stewardship should decide its place. A VigiBase case-control analysis of nearly 30,000 lithium reports found renal, endocrine, gastrointestinal, skin and cardiac reactions were proportionally more often reported in children than with second-generation antipsychotics, thyroid reactions especially. A phase 1 study of elecoglipron, an investigational oral small-molecule GLP-1 agonist, found food did not meaningfully change exposure and the half-life of about 21 hours supports once-daily dosing. The FDA lists a Class II recall of compounded tirzepatide multi-dose vials from Apothecary Pharma for lack of sterility assurance. The pearl covers lithium monitoring and interactions.